- Home
- RBOT vs ASRT Comparison
RBOT vs ASRT Comparison
Compare RBOT & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | ASRT |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 75.1M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | RBOT | ASRT |
|---|---|---|
| Price | $2.45 | $0.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.00 | $3.00 |
| AVG Volume (30 Days) | 156.6K | ★ 343.3K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $2.36 | $0.51 |
| 52 Week High | $18.97 | $1.01 |
Technical Indicators
Market Signals| Indicator | RBOT | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 32.55 | 41.43 |
| Support Level | $2.36 | $0.75 |
| Resistance Level | $3.07 | $0.80 |
| Average True Range (ATR) | 0.33 | 0.04 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 2.31 | 25.45 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.